Intelligence · Clinical Pipeline
Oncology · Phase II
Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.
- Programs
- 2,640
Quick answer
Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- First People's Hospital 261 programs
- Chinese Academy of 199 programs
- George Institute for 119 programs
- United Therapeutics Europe 112 programs
- Telethon Foundation 91 programs
- Takeda 79 programs
- Regeneron UK 71 programs
- MSD Merck Sharp 63 programs
- Ningbo Cancer Hospital 62 programs
- Anaxis Pharma 57 programs
- AstraZeneca 52 programs
- HOFFMANN-LA ROCHE 50 programs
-
gemcitabine and oxaliplatin.
The First People's Hospital of Lianyungang
Gallbladder Carcinoma
1 trial -
genexolPM + cisplatin
Solid Biosciences
Locally Advanced Head and Neck Squamous Cell Carcinoma
1 trial -
hyperbaric oxygen
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
imvotamab
ADC Therapeutics SA
Non-Hodgkin Lymphoma
1 trial -
indibulin
Alaunos Therapeutics
Advanced Solid Tumors
2 trials -
infusion of MYOCET
Teva Pharma GmbH
Cerebral Lymphoma B Cell Refractory
1 trial -
inhaled delta-8-THC 300mcg or 600mcg per dose
Teva Pharma GmbH
Cancer
1 trial -
interleukin-4 PE38KDEL cytotoxin
NEUROCRINE BIOSCIENCES INC
Brain and Central Nervous System Tumors
1 trial -
intravenous infusion (IV) of Adebrelimab (ADE)
The First People's Hospital of Lianyungang
Advanced Hepatocellular Carcinoma (HCC)
1 trial -
ipatasertib
United Therapeutics Europe Ltd
Solid Tumor
1 trial -
ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab
Second Affiliated Hospital of Soochow University
Liver Cancer
1 trial -
irradiation
Ultragenyx UK Limited
Brain Neoplasms
1 trial -
ivosidenib and nivolumab
Agios Netherlands B.V.
Advanced Solid Tumor
1 trial -
lenalidomide combined with rituximab
The First People's Hospital of Lianyungang
Diffuse Large B Cell Lymphoma
1 trial -
leucovorin, oxaliplatin, docetaxel, S-1
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric Cancer
1 trial -
linrodostat mesylate; IDO1 inhibitor, linrodostat mesylate; IDO1 inhibitor, Ipilimumab, Relatlimab intravenous, OPDIVO 10 mg/mL concentrate for solution for infusion., linrodostat mesylate; IDO1 inhibitor, Ipilimumab
Bristol-Myers Squibb Australia Pty Ltd
Advanced Malignant Tumors
1 trial -
long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations
BEONE MEDICINES AUS PTY LTD
Colorectal Neoplasms
1 trial -
lurbinectedin, JEMPERLI 500 mg concentrate for solution for infusion
The George Institute
Advanced/Recurrent Endometrial Cancer Patients with Disease Progression after Prior Therapy with Platinum-based Chemotherapy
1 trial -
lymphokine-activated killer cells
LISATA THERAPEUTICS, INC.
Brain and Central Nervous System Tumors
1 trial -
mFOLFOX6 + BIBF 1120
Galmed Pharmaceuticals
Colorectal Cancer
1 trial -
mFOLFOXIRI
The First People's Hospital of Lianyungang
Locally Advanced Rectal Cancer
1 trial -
mRNA-4157, BCG VACCINE
Merck Sharp and Dohme
Bladder cancer
1 trial -
megestrol acetate oral suspension + serplulimab + SOX
The First People's Hospital of Lianyungang
Stage III Gastric Cancer
1 trial -
mitoxantrone liposome 16 and azacitidine
NovaBridge Biosciences
Angioimmunoblastic T-cell Lymphoma
1 trial -
nab-paclitaxel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
nal-IRI /Experimental
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Metastatic Gastric Adenocarcinoma
1 trial -
nanoliposomal irinotecan
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Head & Neck Cancer
1 trial -
nanoparticle albumin-bound paclitaxel/carboplatin
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
nedaplatin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Central Nervous System Tumors
1 trial -
neoadjuvant anti-PD-1
Shanghai Chest Hospital
Esophageal Cancer
1 trial -
neratinib
PUMA BIOTECHNOLOGY, INC.
Breast Neoplasms
3 trials -
neratinib
PUMA BIOTECHNOLOGY, INC.
HER2-mutant Non-Small Cell Lung Cancer
1 trial -
nilotinib
United Therapeutics Europe Ltd
Mucosal Lentiginous Melanoma
1 trial -
nivolumab
Bristol-Myers Squibb
Neoplasms by Site
1 trial -
nivolumab, ipilimumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatocellular Carcinoma (HCC)
1 trial -
oncolytic adenovirus expressing GMCSF
CG Oncology
Bladder Cancer
1 trial -
ondansetron
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma (HCC)
1 trial -
online adaptive radiotherapy
The First People's Hospital of Lianyungang
Cervical Cancer
1 trial -
orelabrutinib combined with rituximab regimen
The First People's Hospital of Lianyungang
Marginal Zone Lymphoma(MZL)
1 trial -
osimertinib
AstraZeneca
Carcinoma
1 trial -
osimertinib mesylate tablets and anlotinib hydrochloride capsules
The First People's Hospital of Lianyungang
Non Small Cell Lung Cancer
1 trial -
oxaliplatin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Stomach Neoplasms
1 trial -
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
Takeda
Colorectal Carcinoma
1 trial -
pCAR-19B cells
Chongqing Precision Biotech Co., Ltd
Acute Lymphoblastic Leukemia
2 trials -
pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine
United Therapeutics Europe Ltd
Anatomic Stage I Breast Cancer AJCC v8
1 trial -
paclitaxel/carboplatin/lapatinib
Hospital Authority, Hong Kong
ErbB2-Positive Stage I-III Breast Cancer
1 trial -
palifosfamide
Alaunos Therapeutics
Adult Central Nervous System Germ Cell Tumor
1 trial -
pazopanib (GW786034)
GlaxoSmithKline
Neoplasms, Uterine Cervix
1 trial
Frequently asked questions
How many oncology Phase II programs exist?
2,640 programs match both the therapeutic area and stage filters in our published index.
Data attribution: Data sources · All pipeline programs